Autonomix Medical, Inc. (AMIX)
CIK 1617867 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 971,043 shares as of Aug 6, 2026 (10-Q). Share count fell from 23.0M to 1.2M between Aug 2, 2024 and Nov 4, 2024, a pattern consistent with a reverse split (roughly 1-for-20); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Series C Warrants | 428,731 | $18.0747 | 5.5y | — |
| Existing Warrants | 428,731 | $6 | — | — |
| New Series D1 Warrants | 428,731 | not tagged | — | — |
| New Series D2 Warrants | 428,731 | not tagged | — | — |
| November2025 Prefunded Warrants | 214,366 | $0.021 | — | — |
| Series B Warrants | 70,366 | $36.183 | — | — |
| Modified Existing Warrants | 29,649 | $0.021 | 5.5y | — |
| Existing Warrants At1723 Exercise Price | 29,649 | $36.162 | — | — |
| Representatives Warrants | 8,606 | $56.091 | 5y | — |
| the Warrant | 3,810 | $0.42 | 5y | — |
| Series A Warrants | 2,643 | $137.34 | 5y | — |
| Common Warrants | 1,582 | not tagged | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 13, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 25,003 underlying shares, as reported Mar 31, 2026 (10-K).
Reported exercise price: $0.01 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 996,046 = 971,043 O/S + 25,003 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| the Notes | $2.0M | — | $840 | — | ~2,381 sh |
If every note above converted at its tagged price: ~2,381 new shares on 971,043 currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 13, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 971,043 | Aug 6, 2026 |
| + Series C Warrants (if exercised) | 428,731 | Jun 30, 2026 |
| + Existing Warrants (if exercised) | 428,731 | Jul 13, 2026 |
| + New Series D1 Warrants (if exercised) | 428,731 | Jul 13, 2026 |
| + New Series D2 Warrants (if exercised) | 428,731 | Jul 13, 2026 |
| + November2025 Prefunded Warrants (if exercised) | 214,366 | Nov 18, 2025 |
| + Series B Warrants (if exercised) | 70,366 | Jun 30, 2026 |
| + Modified Existing Warrants (if exercised) | 29,649 | Jul 21, 2025 |
| + Existing Warrants At1723 Exercise Price (if exercised) | 29,649 | Jul 21, 2025 |
| + Representatives Warrants (if exercised) | 8,606 | Jun 30, 2026 |
| + the Warrant (if exercised) | 3,810 | Jan 29, 2024 |
| + Series A Warrants (if exercised) | 2,643 | Jun 30, 2026 |
| + Common Warrants (if exercised) | 1,582 | Jun 30, 2026 |
| + the Notes (if fully converted) | 2,381 | Sep 9, 2023 |
| Fully diluted estimate | 3.0M | +214.0% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $19.1Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 5 executed · 5 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full AMIX workspace